Research

Hormonal

Semaglutide treatment (1.7-2.4 mg weekly) in patients with hypothalamic obesity secondary to craniopharyngioma produces sustained, clinically significant weight loss (median 16%) and improves metabolic biomarkers (HbA1c, LDL) over 24 months.

For patients with hypothalamic obesity, semaglutide (1.7-2.4 mg weekly) is an effective long-term treatment for weight loss and metabolic health. It is crucial to maintain consistent dosing, as interruptions can lead to fat mass regain. Side effects are generally mild and manageable.

ModerateSupportsMEDIUM confidence
After 24 months, median weight loss was 16% (95% CI: 8 to 34%, p = 0.004)... Hemoglobin A1c and LDL cholesterol declined by 6.4 mmol/mol (95% CI: 2.3 to 9.9, p = 0.016) and 0.5 mmol/L (95% CI: 0.3 to 0.7, p = 0.012).
Erlend Gjersdal et al. · Pituitary · 2025

Why this rating

Small case series (n=4), but with long-term (24 months) follow-up and objective biomarkers.

Source

Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life

Erlend Gjersdal et al. · Pituitary · 2025

DOI 10.1007/s11102-025-01564-7

case_series · n=4Cited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →